AKT1 and cancer: Cetuximab and panitumumab, therapeutic monoclonal antibodies (mAb) against epidermal growth factor receptor (HER1/EGFR), are frequently used, but are less effective in a subset of cancers with KRAS mutations.6 In clinical trials in patients with KRAS‐mutated CRC, multiple combination therapies such as AKT inhibitor‐MEK inhibitor,7 MEK inhibitor‐FOLFIRI,8 and cetuximab‐FOLFOX9 have shown disappointing results.